Cancer drug setback tarnishes AstraZeneca's R&D claims
June 26, 2014 at 06:31 AM EDT
* U.S. experts vote against accelerated approval of olaparib
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.